RxTrials Institute Drug Pipeline Alert

Allergy Therapeutics saw positive results from its Phase III study of Pollinex Quattro Ragweed in treating allergic conditions.

The double-blind, placebo-controlled study enrolled 993 patients in 85 centers in the U.S. and Canada. Subjects were randomized to receive Pollinex Quattro Ragweed or placebo.

Due to a clinical hold placed on the study by the FDA after an adverse event occurred in a previous study, only 381 patients received all four injections. The study met its primary endpoint by demonstrating a 12 percent benefit over placebo in this complete treatment group, the company said.